Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials

Rocio Sedano; Malcolm Hogan; Cassandra McDonald; Tina Aswani-Omprakash; Christopher Ma; Vipul Jairath

doi:10.1093/ibd/izab362

Underrepresentation of Minorities and Lack of Race Reporting in Ulcerative Colitis Drug Development Clinical Trials

Inflamm Bowel Dis. 2022 Aug 1;28(8):1293-1295. doi: 10.1093/ibd/izab362.

Authors

Rocio Sedano^{1

2}, Malcolm Hogan², Cassandra McDonald³, Tina Aswani-Omprakash⁴, Christopher Ma^{2

5}, Vipul Jairath^{1

2

6}

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Western University, London, ON, Canada.
² Alimentiv, London, ON, Canada.
³ Lawson Health Research Institute, Western University, London, ON, Canada.
⁴ Independent patient advocate, New York, NY, USA.
⁵ Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada.
⁶ Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.

PMID: 35078220
DOI: 10.1093/ibd/izab362

No abstract available

Keywords: clinical trials; inflammatory bowel disease; race and ethnicity; ulcerative colitis.

Plain language summary

Historically, inflammatory bowel disease trials report high rates of White patients enrollment. To promote initiatives toward diversifying the enrolled population, we assessed the reporting of race and ethnicity of patients enrolled in pharmaceutical clinical trials for ulcerative colitis.

MeSH terms

Clinical Trials as Topic
Colitis, Ulcerative* / drug therapy
Crohn Disease* / drug therapy
Drug Development
Humans
Minority Groups